Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9957369 | 0.81 | PIK3CA (0.38) | CDK2PIK3CAPIK3R1MTORDYRK1A | |
| SCHEMBL9957630 | 0.77 | PIK3C3 (0.58) | PIK3CAADORA2APIK3CDPIK3CGPIK3C3 | |
| SCHEMBL9957523 | 0.75 | LMNA (0.51) | CDK2CDK4CCNE1PIK3CAPIK3R1 | |
| SCHEMBL9956209 | 0.74 | GHSR (0.37) | PIK3CAMAPTPIK3CDPIK3CGPIK3C3 | |
| SCHEMBL3642814 | 0.74 | CDK2 (0.38) | CDK2CDK4CCNE1PIK3CAPIK3R1 | |
| SCHEMBL8234099 | 0.73 | DYRK1A (0.35) | CDK2DYRK1AGSK3BALDH1A1CDK5 | |
| SCHEMBL15653814 | 0.71 | CDK4 (0.50) | CDK2CDK4CCNE1DYRK1AGSK3B | |
| SCHEMBL10564099 | 0.69 | NOS3 (0.34) | KDM4EHSP90AA1 | |
| SCHEMBL9957239 | 0.69 | PIK3C3 (0.64) | CDK2CDK4CCNE1PIK3CAAURKA | |
| SCHEMBL23494352 | 0.67 | HTT (0.41) | PIK3CAPIK3R1MTORACHEDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655340-B1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| EP-2655340-B1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20130338159-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| EP-2655340-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | Novartis AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | CDK2 2400/4885CDK4 1560/4885CCNE1 3374/4885 |
| US-20130338159-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | CDK2 2365/4885CDK4 1488/4885CCNE1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.